September 18-20, 2018
Register This Week & Save $600
Developing blood-brain barrier (BBB) crossing therapeutics is challenging, but the potential rewards for success are huge, given the unmet need currently in a range of neurological diseases. An increasing amount of evidence suggests that by using efficient delivery methods such as Trojan-horse shuttles bispecific antibodies and other biologics can effectively cross the BBB, providing an interesting and novel application for these technologies.
Attend this workshop to gain valuable insights into:
The current landscape of the field: How advanced are BBB-crossing bispecifics and what are most promising strategies?
Krzysztof Wicher, Principal Scientist & Group Leader, Ossianix
Multispecific formats clearly demonstrate opportunities to achieve a greater efficacy than combinations of individual mAbs in engaging the immune system, including targeting checkpoint modulating targets. Investigating the underlying biology of the indication and how designs can incorporate this is essential in establishing target combinations to create effective immuno-oncology therapeutics.
Addressing the key challenge of the developing rational designs, this workshop will:
Paul Moore, VP, Cell Biology & Immunology, MacroGenics
The clinical development of novel bispecific approaches has no doubt been hindered by a variety of developability and delivery challenges. Innovative novel approaches aim to address this issue by administering mRNA or DNA encoding the bispecific construct, enabling the patient’s body to produce the therapeutic.
This workshop will provide an in-depth analysis of these approaches, shedding light on issues such as:
Investigating preclinical evidence supporting these approaches and the issues that still need to be overcome
Daniel Hofmann, Scientist, BioNTech
Christine Engeland, Cancer Researcher, National Center for Tumor Diseases
Analyzing anti-drug-antibody (ADA) responses and the integrity of your bispecific format is of paramount importance in the preclinical and clinical development of any bispecific antibody and the selection of the right bioanalytical tools to address the question you would like to answer is a key consideration of this process.
Attend this workshop and:
Discuss different pharmacokinetic assays
Dragan Grabulovski, CEO & Founder, Grabulovski Consulting Services
Wibke Lembke, Associate Director Development, Covagen